Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Mechanism by Which Exogenous Administration of Flt3 Ligand (FL) Expands Natural Killer Cells In Vivo .

Martin Guimond, PhD, Aharon G. Freud, PhD, Hsiaoyin C. Mao, MSc, Bradley W. Blaser, PhD, Gerritt Gerritt Lagemann, MD, Jeffrey B. Vandeusen, PhD, Adrienne Dorrance, PhD, Amy K. Ferketich, PhD, Marta Cavalcanti, MD, Crystal L. Mackall, MD, Michael A. Caligiuri, MD

Blood (2007) 110 (11): 2310.

https://doi.org/10.1182/blood.V110.11.2310.2310

Published: 2007

Journal Articles

Improved Clinical Outcome and ADAMTS13 Activity after Concurrent Cyclosporine and Plasma Exchange in TTP.

Spero R. Cataland, MD, Eric H. Kraut, MD, Don Benson, MD, PhD, Amy K. Ferketich, PhD, April Horne, Ming Jin, PhD, James N. George, MD, Haifeng M. Wu, MD

Blood (2006) 108 (11): 1056.

https://doi.org/10.1182/blood.V108.11.1056.1056

Published: 2006

Journal Articles

Cyclosporine and Plasma Exchange Is Superior to Corticosteroids and Plasma Exchange as Initial Therapy of TTP.

Spero R. Cataland, MD, Ming Jin, PhD, Amy K. Ferketich, PhD, Eric H. Kraut, MD, James N. George, MD, Haifeng M. Wu, MD

Blood (2005) 106 (11): 1235.

https://doi.org/10.1182/blood.V106.11.1235.1235

Published: 2005

Journal Articles

Cyclosporine Alone for the Treatment of Early Recurrences of TTP.

Spero R. Cataland, MD, Ming Jin, PhD, Amy K. Ferketich, PhD, X. Long Zheng, MD, PhD, James N. George, MD, Haifeng M. Wu, MD

Blood (2005) 106 (11): 1236.

https://doi.org/10.1182/blood.V106.11.1236.1236

Published: 2005

Journal Articles

A Novel Human CD34(+) Subset That Constitutively Expresses the High Affinity Interleukin-2 Receptor Traffics to Lymph Nodes and Differentiates into CD56 Bright Natural Killer Cells.

Aharon G. Freud, Brian Becknell, Sameek Roychowdhury, Hsiaoyin C. Mao, Amy K. Ferketich, PhD, Gerard J. Nuovo, MD, Tiffany L. Hughes, Trent B. Marburger, John Sung, Robert A. Baiocchi, MD, PhD, Martin Guimond, Michael A. Caligiuri, MD

Blood (2004) 104 (11): 314.

https://doi.org/10.1182/blood.V104.11.314.314

Published: 2004

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Mechanism by Which Exogenous Administration of Flt3 Ligand (FL) Expands Natural Killer Cells In Vivo .

Improved Clinical Outcome and ADAMTS13 Activity after Concurrent Cyclosporine and Plasma Exchange in TTP.

Cyclosporine and Plasma Exchange Is Superior to Corticosteroids and Plasma Exchange as Initial Therapy of TTP.

Cyclosporine Alone for the Treatment of Early Recurrences of TTP.

A Novel Human CD34(+) Subset That Constitutively Expresses the High Affinity Interleukin-2 Receptor Traffics to Lymph Nodes and Differentiates into CD56 Bright Natural Killer Cells.

Email alerts

ASH Publications

American Society of Hematology

Update search

Mechanism by Which Exogenous Administration of Flt3 Ligand (FL) Expands Natural Killer Cells In Vivo .

Improved Clinical Outcome and ADAMTS13 Activity after Concurrent Cyclosporine and Plasma Exchange in TTP.

Cyclosporine and Plasma Exchange Is Superior to Corticosteroids and Plasma Exchange as Initial Therapy of TTP.

Cyclosporine Alone for the Treatment of Early Recurrences of TTP.

A Novel Human CD34(+) Subset That Constitutively Expresses the High Affinity Interleukin-2 Receptor Traffics to Lymph Nodes and Differentiates into CD56 Bright Natural Killer Cells.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only